Hepatocellular Carcinoma

Key clinical point: Health-related quality of life was preserved longer in HCC patients treated with transarterial radioembolization (TARE) compared to those treated with sorafenib.

Major finding: The median time to deterioration in global health status was 3.9 months in TARE patients, vs 2.6 months in sorafenib patients. TARE patients also showed less deterioration in measures of physical functioning, role functioning, and social functioning compared to sorafenib patients.

Study details: The data come from 285 adults who were participants in a randomized trial of transarterial radioembolization (122 patients) or sorafenib (163 patients) for the treatment of locally advanced or inoperable HCC. Quality of life was assessed from the date of randomization until disease progression or study discontinuation, using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire.

Disclosures: The study received no outside funding. Lead author Dr. Pereira had no financial conflicts to disclose.

Source: Pereira H et al. Eur J Cancer. 2021 Jul 6. doi: 10.1016/j.ejca.2021.05.032.

Key clinical point: Health-related quality of life was preserved longer in HCC patients treated with transarterial radioembolization (TARE) compared to those treated with sorafenib.

Major finding: The median time to deterioration in global health status was 3.9 months in TARE patients, vs 2.6 months in sorafenib patients. TARE patients also showed less deterioration in measures of physical functioning, role functioning, and social functioning compared to sorafenib patients.

Study details: The data come from 285 adults who were participants in a randomized trial of transarterial radioembolization (122 patients) or sorafenib (163 patients) for the treatment of locally advanced or inoperable HCC. Quality of life was assessed from the date of randomization until disease progression or study discontinuation, using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire.

Disclosures: The study received no outside funding. Lead author Dr. Pereira had no financial conflicts to disclose.

Source: Pereira H et al. Eur J Cancer. 2021 Jul 6. doi: 10.1016/j.ejca.2021.05.032.

Key clinical point: Health-related quality of life was preserved longer in HCC patients treated with transarterial radioembolization (TARE) compared to those treated with sorafenib.

Major finding: The median time to deterioration in global health status was 3.9 months in TARE patients, vs 2.6 months in sorafenib patients. TARE patients also showed less deterioration in measures of physical functioning, role functioning, and social functioning compared to sorafenib patients.

Study details: The data come from 285 adults who were participants in a randomized trial of transarterial radioembolization (122 patients) or sorafenib (163 patients) for the treatment of locally advanced or inoperable HCC. Quality of life was assessed from the date of randomization until disease progression or study discontinuation, using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire.

Disclosures: The study received no outside funding. Lead author Dr. Pereira had no financial conflicts to disclose.

Source: Pereira H et al. Eur J Cancer. 2021 Jul 6. doi: 10.1016/j.ejca.2021.05.032.

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Key clinical point: Overall survival, cancer-specific survival, and 3-year recurrence-free survival rates were similar in patients with early treated microwave ablation (MWA) or robot-assisted hepatectomy (RH).

Major finding: The 3-year recurrence-free survival, overall survival, and cancer-specific survival in patients treated with MWA and RH were 52.2% and 65.8%, 91.5% and 91.3%, and 91.5% and 91.3%, respectively. 

Study details: The data come from 401 adults with early hepatocellular carcinoma treated with microwave ablation (240) or robot-assisted hepatectomy (161).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ding W et al. Dig Liver Dis. 2021 Jul 6. doi: 10.1016/j.dld.2021.04.008.

Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.

Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.

Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.

Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.

Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.

Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.

Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.

Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.

Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.

Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.

Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.

Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.

Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.

Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.

Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.

Key clinical point: For HCC patients treated with DEB-TACE, size or concentration of microspheres did not affect overall survival, but doxorubicin concentration did impact factors including treatment response and hospital stay.

Major finding: A total of 23 patients achieved complete response (CR), 32 achieved a partial response, 18 had stable disease, and 14 had progressive disease; no difference in treatment response was noted between 75-µm and 100-µm groups, but patients treated with half-loaded doxorubicin had significantly higher CR (53.3% vs 20.8%) and shorter hospital stays (1.7 days vs. 2.2 days) than patients treated with full-loaded doxorubicin.

Study details: The data come from a retrospective study of 87 adults with HCC who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) with half-loaded or full-loaded doxorubicin in 75-µm or 100-µm microspheres.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lin C-Y et al. Sci Rep. 2021 Jun 10. doi: 10.1038/s41598-021-91021-9.

Key clinical point: For HCC patients treated with DEB-TACE, size or concentration of microspheres did not affect overall survival, but doxorubicin concentration did impact factors including treatment response and hospital stay.

Major finding: A total of 23 patients achieved complete response (CR), 32 achieved a partial response, 18 had stable disease, and 14 had progressive disease; no difference in treatment response was noted between 75-µm and 100-µm groups, but patients treated with half-loaded doxorubicin had significantly higher CR (53.3% vs 20.8%) and shorter hospital stays (1.7 days vs. 2.2 days) than patients treated with full-loaded doxorubicin.

Study details: The data come from a retrospective study of 87 adults with HCC who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) with half-loaded or full-loaded doxorubicin in 75-µm or 100-µm microspheres.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lin C-Y et al. Sci Rep. 2021 Jun 10. doi: 10.1038/s41598-021-91021-9.

Key clinical point: For HCC patients treated with DEB-TACE, size or concentration of microspheres did not affect overall survival, but doxorubicin concentration did impact factors including treatment response and hospital stay.

Major finding: A total of 23 patients achieved complete response (CR), 32 achieved a partial response, 18 had stable disease, and 14 had progressive disease; no difference in treatment response was noted between 75-µm and 100-µm groups, but patients treated with half-loaded doxorubicin had significantly higher CR (53.3% vs 20.8%) and shorter hospital stays (1.7 days vs. 2.2 days) than patients treated with full-loaded doxorubicin.

Study details: The data come from a retrospective study of 87 adults with HCC who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) with half-loaded or full-loaded doxorubicin in 75-µm or 100-µm microspheres.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lin C-Y et al. Sci Rep. 2021 Jun 10. doi: 10.1038/s41598-021-91021-9.

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.

Key clinical point: Overall survival rates were similar in patients with intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) in a multivariate analysis. However, iCCA patients had better overall survival in a subgroup analysis of patients with poor prognostic features such as tumor size and lymph node involvement.

Major finding: Overall survival was 9 months for iCCA vs. 13 months for HCC, but this difference lost significance in multivariate analysis. In a subgroup analysis, overall survival was greater in iCCA compared to HCC for patients with tumors of 5 cm or larger (adjusted hazard ratio 0.83), lymph node involvement (aHR 0.76), distant metastasis (aHR 0.76), poorly/undifferentiated tumors (aHR 0.88) and patients receiving non-curative treatment (aHR 0.96).

Study details: The data come from the Surveillance, Epidemiology, and End Results Program 18 Database (2000-2017), and the study population included 13,611 iCCA patients and 96,151 HCC patients. 

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose

Source: Lee Y-T et al. Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.

Key clinical point: A combination of atezolizumab plus bevacizumab showed therapeutic potential for adults with unresectable HCC, as patients showed a strong initial therapeutic response; the most common adverse events were appetite loss, fatigue, and urine protein.

Major finding: After 6 weeks, the overall objective response rate for early tumor shrinkage was 10.6% and the disease control rate was 79.6%; results were similar for the subset of patients with no prior history of systemic treatment (9.7% and 12.2%).

Study details: The data come from a retrospective study of 171 adults with unresectable hepatocellular carcinoma who were treated with a combination of atezolizumab plus bevacizumab; 75 of these had no prior history of systemic treatment.

Disclosures: The study was supported by the Institutional Ethics Committee of Ehime Prefectural Central Hospital. The researchers had no financial conflicts to disclose.

Source: Hiraoka A et al. Cancer Rep. 2021 Jun 11. doi: 10.1002/cnr2.1464. 

Key clinical point: A combination of atezolizumab plus bevacizumab showed therapeutic potential for adults with unresectable HCC, as patients showed a strong initial therapeutic response; the most common adverse events were appetite loss, fatigue, and urine protein.

Major finding: After 6 weeks, the overall objective response rate for early tumor shrinkage was 10.6% and the disease control rate was 79.6%; results were similar for the subset of patients with no prior history of systemic treatment (9.7% and 12.2%).

Study details: The data come from a retrospective study of 171 adults with unresectable hepatocellular carcinoma who were treated with a combination of atezolizumab plus bevacizumab; 75 of these had no prior history of systemic treatment.

Disclosures: The study was supported by the Institutional Ethics Committee of Ehime Prefectural Central Hospital. The researchers had no financial conflicts to disclose.

Source: Hiraoka A et al. Cancer Rep. 2021 Jun 11. doi: 10.1002/cnr2.1464. 

Key clinical point: A combination of atezolizumab plus bevacizumab showed therapeutic potential for adults with unresectable HCC, as patients showed a strong initial therapeutic response; the most common adverse events were appetite loss, fatigue, and urine protein.

Major finding: After 6 weeks, the overall objective response rate for early tumor shrinkage was 10.6% and the disease control rate was 79.6%; results were similar for the subset of patients with no prior history of systemic treatment (9.7% and 12.2%).

Study details: The data come from a retrospective study of 171 adults with unresectable hepatocellular carcinoma who were treated with a combination of atezolizumab plus bevacizumab; 75 of these had no prior history of systemic treatment.

Disclosures: The study was supported by the Institutional Ethics Committee of Ehime Prefectural Central Hospital. The researchers had no financial conflicts to disclose.

Source: Hiraoka A et al. Cancer Rep. 2021 Jun 11. doi: 10.1002/cnr2.1464. 

Key clinical point: Overall, fatigue, frustration, and fear were the most prevalent experiences across all disease stages; abdominal pain and skin-related issues also were frequently reported by patients with stage C HCC.

Major finding: All participants reported fatigue, and 21 of 25 discussed it without prompting; the mean disturbance rating was 8.2. Abdominal pain was the most disturbing symptom, reported by 14 participants with a mean disturbance rating of 9.0.

Study details: The data come from interviews with 25 adults with hepatocellular carcinoma living in the United States; 68% were men, the median age was 63 years. Of these, 12% had stage A liver cancer, 32% had stage B, and 56% had stage C.

Disclosures: The study was funded by AstraZeneca; the lead author and several coauthors are employees of AstraZeneca and own shares in the company.

Source: Patel N et al. Qual Life Res. 2021 Jun 11. doi: 10.1007/s11136-021-02903-4.

Key clinical point: Overall, fatigue, frustration, and fear were the most prevalent experiences across all disease stages; abdominal pain and skin-related issues also were frequently reported by patients with stage C HCC.

Major finding: All participants reported fatigue, and 21 of 25 discussed it without prompting; the mean disturbance rating was 8.2. Abdominal pain was the most disturbing symptom, reported by 14 participants with a mean disturbance rating of 9.0.

Study details: The data come from interviews with 25 adults with hepatocellular carcinoma living in the United States; 68% were men, the median age was 63 years. Of these, 12% had stage A liver cancer, 32% had stage B, and 56% had stage C.

Disclosures: The study was funded by AstraZeneca; the lead author and several coauthors are employees of AstraZeneca and own shares in the company.

Source: Patel N et al. Qual Life Res. 2021 Jun 11. doi: 10.1007/s11136-021-02903-4.

Key clinical point: Overall, fatigue, frustration, and fear were the most prevalent experiences across all disease stages; abdominal pain and skin-related issues also were frequently reported by patients with stage C HCC.

Major finding: All participants reported fatigue, and 21 of 25 discussed it without prompting; the mean disturbance rating was 8.2. Abdominal pain was the most disturbing symptom, reported by 14 participants with a mean disturbance rating of 9.0.

Study details: The data come from interviews with 25 adults with hepatocellular carcinoma living in the United States; 68% were men, the median age was 63 years. Of these, 12% had stage A liver cancer, 32% had stage B, and 56% had stage C.

Disclosures: The study was funded by AstraZeneca; the lead author and several coauthors are employees of AstraZeneca and own shares in the company.

Source: Patel N et al. Qual Life Res. 2021 Jun 11. doi: 10.1007/s11136-021-02903-4.

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Key clinical point: HCC patients with a higher expression of microRNA-889 had lower overall survival rates compared to those with low expression of miR-889.

Major finding: Overexpression of miR-889 significantly increased HCC cell proliferation, migration, and invasion in HCC cell lines, and overall survival was lower in the high expression of miR-889 (P = 0.013).

Study details: The data come from analysis of 113 fresh specimens of HCC and para-cancerous benign tissue from 113 patients with HCC who underwent partial or total hepatectomy between January 2010 and June 2015 at a single center.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Wang H et al. Diagn Pathol. 2021 Jun 11. doi: 10.1186/s13000-021-01111-5.

Key clinical point: HCC patients with a higher expression of microRNA-889 had lower overall survival rates compared to those with low expression of miR-889.

Major finding: Overexpression of miR-889 significantly increased HCC cell proliferation, migration, and invasion in HCC cell lines, and overall survival was lower in the high expression of miR-889 (P = 0.013).

Study details: The data come from analysis of 113 fresh specimens of HCC and para-cancerous benign tissue from 113 patients with HCC who underwent partial or total hepatectomy between January 2010 and June 2015 at a single center.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Wang H et al. Diagn Pathol. 2021 Jun 11. doi: 10.1186/s13000-021-01111-5.

Key clinical point: HCC patients with a higher expression of microRNA-889 had lower overall survival rates compared to those with low expression of miR-889.

Major finding: Overexpression of miR-889 significantly increased HCC cell proliferation, migration, and invasion in HCC cell lines, and overall survival was lower in the high expression of miR-889 (P = 0.013).

Study details: The data come from analysis of 113 fresh specimens of HCC and para-cancerous benign tissue from 113 patients with HCC who underwent partial or total hepatectomy between January 2010 and June 2015 at a single center.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Wang H et al. Diagn Pathol. 2021 Jun 11. doi: 10.1186/s13000-021-01111-5.